Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)-Reference-Cited by-同舟云学术

Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)

Published:2019-04-19 Issue:2 Volume:176 Page:303-310
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Bellon Jennifer R.,Guo Hao,Barry William T.,Dang Chau T.,Yardley Denise A.,Moy Beverly,Marcom P. Kelly,Albain Kathy S.,Rugo Hope S.,Ellis Matthew,Wolff Antonio C.,Carey Lisa A.,Overmoyer Beth A.,Partridge Ann H.,Hudis Clifford A.,Krop Ian,Burstein Harold J.,Winer Eric P.,Tolaney Sara M.

Funder

Genentech

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05238-4.pdf

Reference20 articles.

1. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423. https://doi.org/10.1073/pnas.0932692100

2. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26(14):2373–2378. https://doi.org/10.1200/JCO.2007.14.4287

3. Millar EK, Graham PH, O’Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27(28):4701–4708. https://doi.org/10.1200/JCO.2008.21.7075